Previous close | 742.40 |
Open | 748.00 |
Bid | 743.30 x 0 |
Ask | 745.70 x 0 |
Day's range | 744.70 - 748.00 |
52-week range | 388.20 - 751.40 |
Volume | |
Avg. volume | 13 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
After an eventful week compounded by Nvidia's (NVDA) fiscal first-quarter earnings, the major market averages (^DJI, ^IXIC, ^GSPC) are hoping to end the week on a high note and claw back some gains ahead of the Memorial Day Weekend. Morning Brief Hosts Seana Smith and Brad Smith walk investors through the top stories moving stocks in Friday's trading day, kicking off the session with Truist Co-Chief Investment Officer and Chief Market Strategist Keith Lerner who compares the market sway of Nvidia's latest earnings to that of inflation data or the Federal Reserve's monetary policy. The Securities and Exchange Commission (SEC) approved ether ETF offerings on Thursday, leading Bloomberg Intelligence ETF Research Analyst James Seyffart to believe ethereum-exposed (ETH-USD) products will have similar success to the spot bitcoin ETFs (BTC-USD) rolled out at the start of 2024, just not on the same scale. Other top trending stories include the latest in the Department of Justice's (DOJ) antitrust suit against concert promoter and ticket seller Live Nation (LYV) and Charter Communications' (CHTR) content distribution deal with Paramount Global (PARA). This post was written by Luke Carberry Mogan.
Stocks (^DJI, ^IXIC, ^GSPC) edge higher at Friday's open, hoping to reclaim slight losses ahead of the long Memorial Day Weekend. Yahoo Finance Senior Markets Reporter Jared Blikre joins the Morning Brief to examine the market direction and this morning's across-the-board sector gains. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
Friday, Eli Lilly And Company (NYSE:LLY) announced it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion. This expansion will enhance Lilly’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection. Related: Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires M